Heraeus CO2 Incubator BBD 6220
...ries and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and optimum reproducibility of results....SenoScan TrueView Digital Mammography
...ved, and represents a breakthrough in early breast cancer detection. It is the first and only mammography system to offer 25-micron native diagnostic resolution - the highest available. SenoScan's larger field of view accommodates more patients. Its curved breast support is more comfortable and helps reduce......pproximately 500,000 people die each year of colon cancer - including 57,000 Americans. Despite diagnostic improvements (high contrast berium enema, colonoscopy, FOBT, flexible sigmoidoscopy, etc.) an increase in the success rate of curative treatment for colorectal carcinomas has not been achieved over the...Hemoccult SENSA Fecal Occult Blood Test
...th Hemoccult will reduce mortality from colorectal cancer by 20 to 40 percent....The screening test for colorectal cancer that's simple, convenient, and effective....NMP22® BladderChek® Kit (24-test kit)
...plate enzyme immunoassay that can identify bladder cancer patients who are at risk for rapid recurrence or o... low levels. The majority of patients with bladder cancer release large quantities of NMP22 into their urine....NMP22® BladderChek® Kit (1-test kit)
...plate enzyme immunoassay that can identify bladder cancer patients who are at risk for rapid recurrence or o... low levels. The majority of patients with bladder cancer release large quantities of NMP22 into their urine....... management and prognosis of patients withprostate cancer at various stage of the disease....Total Prostate Specific Antigen
... It is used as an aid in the detection of prostate cancer and in the management of prostate cancer patients.......s the first approved for the detection of prostate cancer when used in combination with digital rectal examination (DRE) in men aged 50 years or older. Depending on the results of your DRE and total PSA test, your physician may decide to order an additional blood test, called free PSA. This test is used to......ate with the volume and clinical stage of prostate cancer [1,4]. Selective determination of the various form...free PSA to PSA-ACT is lower in untreated prostate cancer patients than in normal individuals or in patients with BPH. Thus, in patients with PSA in the 4 to ...Access Hybritech® free PSA Test
...ree PSA will help improve the accuracy of prostate cancer detection. PSA exists in multiple forms in the bl... PSA could further help in distinguishing prostate cancer from benign prostate disease. The Hybritech® free PSA test -- also the first test of it's kind t......ssay for the quantitative determination of ovarian cancer antigen CA125 in human serum...Coat-A-Count AFP IRMA (Alpha Fetoprotein)
...agement of patients withnonseminomatous testicular cancer andother conditions associated with abnormalAFP production; or (b) measurements in maternal serumduring gestational weeks 15 through 21 used in conjunction with ultrasonographyor amniography to aid in the detection offetal open neural tube defects.......ed for use as an aid in the management of bladder cancer patients in conjunction with cytology....TargetScan Targeted Prostate Biopsy System
... latest innovation in prostate mapping, biopsy and cancer treatment guidance. Combining 3-D image acquisitio...ostate biopsies -- potentially improving patients' cancer treatment outcomes with less-invasive procedures.......ted for use as an aid in the management of bladder cancer in conjunction with cystoscopy or when prescribed for in home use.BTA stat Test was cleared by the FDA for prescription home use in February 1999. The BTA stat Test detects a substance produced by bladder tumors, if present in a urine sample.......t-effective way to aid in the detection of bladder cancer in patients at risk. The use of the NMP22 protein has been FDA-approved four times for various formats and claims, most recently in April 2003 for point-of-care use for diagnosis....Lyphochek Tumor Marker Control
...duct designed to assess the performance of various cancer antigen tests, including esoteric tumor markers.......ciding courses of treatment for patients receiving cancer chemotherapy, immunosuppressive treatment, recurring infections and autoimmune dieseases.......ciding courses of treatment for patients receiving cancer chemotherapy, immunosuppressive treatment, recurring infections and autoimmune dieseases. Kit 030 designed especially for patients with autoimmune diseases giving rise to high titers of rheumatoid factors or heterophile antibodies that may interfere...Insulin-like Growth Factor-I (IGF-I) ELISA
...ed increasingly in studies associated with growth, cancer and bone metabolism....Self-Retaining Bicanaliculus Intubation Set
...stenosis. Special consideration should be given to cancer patients on constricting drug therapies such as Taxotere.......ase activity. Approximately 20-30% cases of breast cancer show an amplification and/or over-expression of Her-2/neu in tumor cells. Since the introduction of Herceptin® as a targeted therapy for breast cancer, the clinical testing of Her-2/neu in breast carcinoma has become very important in patient car......cation in formalin-fixed, paraffin-embedded breast cancer tissue specimens. Gene amplification is determined from the ratio between the number of signals from the hybridization of the HER2 gene probe (red signals) and the number of signals from the hybridization of the reference chromosome 17 probe (green s......tic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay performed using formalin-fixed, paraffin-e......ate with the volume and clinical stage of prostate cancer [1,4]. Selective determination of the various form...free PSA to PSA-ACT is lower in untreated prostate cancer patients than in normal individuals or in patients with BPH. Thus, in patients with PSA in the 4 to ...... growing research interest in the role of IGF-I in cancer risk assessment [8.9]. Baxter RC, et al. J Biol Chem 264:11843-11848, 1989. Rechler M. Vit Horm 47:1-114, 1993. Juul A. et al. J Clin Endocrinol Metab 82: 2497-2502, 1997. Lee PDK & Rosenfeld RG. Pediatrician 14:154-161, 1987. Rosenfeld RG, et ...IGF-I ELISA Test (Non-Extraction)
... growing research interest in the role of IGF-I in cancer risk assessment [8.9]. Baxter RC, et al. J Biol Chem 264:11843-11848, 1989. Rechler M. Vit Horm 47:1-114, 1993. Juul A. et al. J Clin Endocrinol Metab 82: 2497-2502, 1997. Lee PDK & Rosenfeld RG. Pediatrician 14:154-161, 1987. Rosenfeld RG, et ...IGF-I IRMA Test (Non-Extraction)
... growing research interest in the role of IGF-I in cancer risk assessment [8.9]. Baxter RC, et al. J Biol Chem 264:11843-11848, 1989. Rechler M. Vit Horm 47:1-114, 1993. Juul A. et al. J Clin Endocrinol Metab 82: 2497-2502, 1997. Lee PDK & Rosenfeld RG. Pediatrician 14:154-161, 1987. Rosenfeld RG, et ...IGF-I ELISA Test (With Extraction)
... growing research interest in the role of IGF-I in cancer risk assessment [8.9]. Baxter RC, et al. J Biol Chem 264:11843-11848, 1989. Rechler M. Vit Horm 47:1-114, 1993. Juul A. et al. J Clin Endocrinol Metab 82: 2497-2502, 1997. Lee PDK & Rosenfeld RG. Pediatrician 14:154-161, 1987. Rosenfeld RG, et ...IGF-I IRMA Test (With Extraction)
... growing research interest in the role of IGF-I in cancer risk assessment [8.9]. Baxter RC, et al. J Biol Chem 264:11843-11848, 1989. Rechler M. Vit Horm 47:1-114, 1993. Juul A. et al. J Clin Endocrinol Metab 82: 2497-2502, 1997. Lee PDK & Rosenfeld RG. Pediatrician 14:154-161, 1987. Rosenfeld RG, et ...... growing research interest in the role of IGF-I in cancer risk assessment [8.9]. Baxter RC, et al. J Biol Chem 264:11843-11848, 1989. Rechler M. Vit Horm 47:1-114, 1993. Juul A. et al. J Clin Endocrinol Metab 82: 2497-2502, 1997. Lee PDK & Rosenfeld RG. Pediatrician 14:154-161, 1987. Rosenfeld RG, et ...BD Cell-Tak Cell and Tissue Adhesive
...d successfully with sperm cells, T47D human breast cancer cells, and neutrophils....Hemoccult ICT Fecal Occult Blood Test
...cult ICT is an ideal screening tool for colorectal cancer (CRC), and this specificity also reduces the number of false positive test results. Safe and non-invasive, Hemoccult ICT is very patient friendly, as there are no diet or drug restrictions for patients to follow while they are using it, which helps i......cult ICT is an ideal screening tool for colorectal cancer (CRC), and this specificity also reduces the number of false positive test results. Safe and non-invasive, Hemoccult ICT is very patient friendly, as there are no diet or drug restrictions for patients to follow while they are using it, which helps i...Physicians' Cancer Chemotherapy Drug Manual 2005
... handbook is an up-to-date guide to all aspects of cancer chemotherapy. The book provides a comprehensive, e...r 100 drugs both on and off label commonly used in cancer treatment. This new edition includes new agents (recently or about to be FDA approved)....Pocket Guide to Chemotherapy Protocols, 2nd Edition
..., nurses, and other health care providers treating cancer patients.......A test for the screening and monitoring of bladder cancer patients. The NMP22 Test Kit is a quantitative microplate enzyme immunoassay that detects elevated levels of NMP22 protein in the urine of patients with bladder cancer, even at early stages of the disease.......est that predicts the risk of metastasis in breast cancer patients. It is based on groundbreaking research performed at the Netherlands Cancer Institute and the Antoni Van Leeuwenhoek Hospital in Amsterdam, The Netherlands....